BR112015008839A2 - tratamento de tumores do sistema nervoso central - Google Patents

tratamento de tumores do sistema nervoso central

Info

Publication number
BR112015008839A2
BR112015008839A2 BR112015008839A BR112015008839A BR112015008839A2 BR 112015008839 A2 BR112015008839 A2 BR 112015008839A2 BR 112015008839 A BR112015008839 A BR 112015008839A BR 112015008839 A BR112015008839 A BR 112015008839A BR 112015008839 A2 BR112015008839 A2 BR 112015008839A2
Authority
BR
Brazil
Prior art keywords
treatment
nervous system
central nervous
system tumors
release
Prior art date
Application number
BR112015008839A
Other languages
English (en)
Inventor
S Bankiewicz Krystof
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112015008839A2 publication Critical patent/BR112015008839A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "tratamento de tumores do sistema nervoso central". um efeito terapêutico sinérgico é obtido em pacientes com câncer do cns tratados concomitantemente com um primeiro agente antineoplásico e um segundo agente antineoplásico, em que um ou ambos os agentes antineoplásicos são administrados por liberação melhorada por convecção. as combinações de interesse incluem, entre outras, a liberação ced de um inibidor de topoisomerase, por exemplo, topotecano, e liberação sistêmica de um triazeno, por exemplo, temozolomida.
BR112015008839A 2012-10-19 2013-10-18 tratamento de tumores do sistema nervoso central BR112015008839A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261716027P 2012-10-19 2012-10-19
PCT/US2013/065734 WO2014063087A1 (en) 2012-10-19 2013-10-18 Treating tumors of the central nervous system

Publications (1)

Publication Number Publication Date
BR112015008839A2 true BR112015008839A2 (pt) 2017-07-04

Family

ID=50488796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008839A BR112015008839A2 (pt) 2012-10-19 2013-10-18 tratamento de tumores do sistema nervoso central

Country Status (8)

Country Link
US (1) US20150258085A1 (pt)
EP (1) EP2908909A1 (pt)
JP (1) JP2015534984A (pt)
CN (1) CN104736201A (pt)
AU (1) AU2013331077A1 (pt)
BR (1) BR112015008839A2 (pt)
CA (1) CA2886064A1 (pt)
WO (1) WO2014063087A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020406B1 (pt) * 2017-03-31 2021-10-26 Fujifilm Corporation Composições lipossômicas, composição farmacêutica que compreende a dita composição lipossômica e uso da mesma para tratar câncer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
JP2005508375A (ja) * 2001-11-09 2005-03-31 ネオファーム、インコーポレイティッド Ｉｌ−１３を発現する腫瘍の選択的治療
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
WO2008020931A2 (en) * 2006-08-08 2008-02-21 Peak Biosciences, Inc. Device for delivery of anti-cancer agents to tissue
US8518930B2 (en) * 2008-07-29 2013-08-27 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central

Also Published As

Publication number Publication date
AU2013331077A1 (en) 2015-04-16
EP2908909A1 (en) 2015-08-26
CN104736201A (zh) 2015-06-24
WO2014063087A1 (en) 2014-04-24
JP2015534984A (ja) 2015-12-07
CA2886064A1 (en) 2014-04-24
US20150258085A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
PH12015500825B1 (en) Substituted benzene compounds
TR201807411T4 (tr) DNA-PK inhibitörleri.
BR112014026703A2 (pt) inibidores de dna-pk
MX2016007351A (es) Terapia de combinacion para tratar cancer.
WO2015009726A3 (en) Medical uses of cd38 agonists
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015006524A2 (pt) derivados de quinazolinona como inibidores de parp
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015002706A8 (pt) Niclosamida e seus derivados para uso no tratamento de tumores sólidos
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
EA201590820A1 (ru) Производные 4-карбоксамидоизоиндолинона в качестве селективных ингибиторов parp-1
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
WO2015148971A3 (en) Method for detecting or treating triple negative breast cancer
MX2016005900A (es) Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer.
BR112015008839A2 (pt) tratamento de tumores do sistema nervoso central
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]